Los Angeles Capital Management’s Myriad Genetics MYGN Stock Holding History

Los Angeles Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$397K	Sell	69,515 -17,665	-20%	-$80.2K	﹤0.01%	976
2026 Q1	$392K	Sell	87,180 -10,239	-11%	-$53.3K	﹤0.01%	948
2025 Q4	$774K	Buy	97,419 +16,023	+20%	+$116K	﹤0.01%	736
2025 Q3	$588K	Buy	+81,396	New	+$483K	﹤0.01%	875
2019 Q3	–	Sell	-39,803	Closed	-$1.11M	–	1332
2019 Q2	$1.11M	Sell	39,803 -18,770	-32%	-$530K	0.01%	818
2019 Q1	$1.95M	Sell	58,573 -7,280	-11%	-$222K	0.01%	662
2018 Q4	$1.91M	Buy	65,853 +6,445	+11%	+$232K	0.01%	565
2018 Q3	$2.73M	Buy	59,408 +41,908	+239%	+$1.86M	0.01%	586
2018 Q2	$654K	Sell	17,500 -8,390	-32%	-$283K	﹤0.01%	1056
2018 Q1	$765K	Buy	25,890 +20,050	+343%	+$678K	﹤0.01%	904
2017 Q4	$201K	Buy	+5,840	New	+$197K	﹤0.01%	1272
2014 Q1	–	Sell	-18,041	Closed	-$379K	–	1291
2013 Q4	$379K	Buy	+18,041	New	+$456K	﹤0.01%	1008

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Los Angeles Capital Management's MYGN Position: Q2 2026 in Review

Los Angeles Capital Management reduced its Myriad Genetics (MYGN) stake by 20% in Q2 2026, selling an estimated $80.2K and leaving 69,515 shares worth $397K. The position accounts for ﹤0.01% of the portfolio, ranked #976.

Los Angeles Capital Management first reported a position in MYGN in Q4 2013 and has held it in 12 quarters since. The position peaked at $2.73M in Q3 2018. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

Los Angeles Capital Management held 69,515 shares of Myriad Genetics worth $397K as of Q2 2026.
Los Angeles Capital Management sold 17,665 Myriad Genetics shares in Q2 2026, an estimated $80.2K.
Myriad Genetics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #976 holding.
Los Angeles Capital Management first reported a position in Myriad Genetics in Q4 2013 and has held it in 12 quarters since.
Los Angeles Capital Management's Myriad Genetics position peaked at $2.73M in Q3 2018.
196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.